-
TOUCH Study – Breakthroughs and Limitations in Chemotherapy-Free Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
Treatment strategies for HR+/HER2+ breast cancer have long been a focus of research. On December 11 (Central Time), during the 47th San Antonio Breast Cancer Symposium (SABCS), the results of the TOUCH study (Abstract RF1-02) were released, drawing significant attention. This international, open-label Phase II trial explored the efficacy of a chemotherapy-free approach in the…
-
SABCS 2024 | Translational Medicine Controversies: Defining Triple-Negative Breast Cancer and Developing Tumor-Agnostic Drugs
Global breast cancer researchers are tackling cutting-edge questions to inform clinical trial design and guide future treatment decisions. At the 2024 San Antonio Breast Cancer Symposium (SABCS), an internationally renowned panel of experts explored two of the most pressing topics in translational medicine—how to define triple-negative breast cancer (TNBC) and the development of tumor-agnostic therapies.
-
Professor Weili Zhao , an Expert in Hematology From China, has Been Honored With the “Charpak-Dubousset Prize”
On December 17, 2024, French time, at the annual award ceremony of the French National Academy of Medicine (ANM), Professor Weili Zhao form Shanghai Ruijin Hospital and Professor Anne Janin from Paris Diderot University jointly received the “Charpak-Dubousset Prize.” The prize was personally presented by Christian Boitard, the Secretary-General of the Académie Nationale de Médecine,…
-
SABCS 2024 | Dr. Zhenzhen Liu: Optimizing Neoadjuvant and Adjuvant Treatment Strategies for HR+/HER2+ Early Breast Cancer in China Through Real-World
The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. As one of the largest and most prestigious scientific gatherings in breast cancer research, SABCS showcases the latest research findings, clinical practices, treatment advancements, and technological innovations in breast cancer from the past year.
-
SABCS 2024 | Dr. Wenbin Zhou: Efficacy of Pyrotinib-Based Regimen in Neoadjuvant Therapy for HER2-Enriched Breast Cancer
Breast cancer remains a leading malignancy threatening women’s health, and optimizing treatment strategies continues to be a major focus of research. Neoadjuvant therapy, especially for HER2-positive breast cancer, plays a key role in improving survival outcomes and quality of life. The 47th San Antonio Breast Cancer Symposium (SABCS) will take place from December 10 to…
-
SABCS 2024 | Dr. Huiping Li & Dr. Hanfang Jiang: Hetrombopag – A New Option for CTIT Treatment in Breast Cancer Patients?
The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, USA. A phase II prospective study led by Professors Huiping Li and Hanfang Jiang from Peking University Cancer Hospital will be presented as a poster (Abstract No: P1-02-12). This study explores the efficacy and safety…
-
SABCS 2024 | Dr. Hui Xie: Exploring the Degradomic Features of Mammary Tumor-Adjacent Adipocytes and MASP6 as a Potential Therapeutic Target
The 47th San Antonio Breast Cancer Symposium (SABCS) will be held from December 10 to 13, 2024, in San Antonio, Texas, USA. As the largest and most influential breast cancer-focused academic meeting globally, the conference will unveil a series of groundbreaking research findings. A study conducted by Dr. Hui Xie and her team from The…
-
CACA-GO | Professor Declan Murphy on Whether Pelvic Lymph Node Dissection for Prostate Cancer Is “Dead”
The 14th Shanghai Genitourinary Oncology Academic Conference and Annual Meeting of Chinese Anti-Cancer Association—Genitourinary Oncology Committee (CACA-GO) recently took place in Shanghai. The conference invited numerous internationally renowned experts in uro-oncology to deliver academic presentations and perform surgical demonstrations. Professor Declan Murphy from the Peter MacCallum Cancer Centre in Australia delivered a compelling talk titled…
Connecting Medical Expertise through Media